ArticleAntimicrobial agents and chemotherapy2026
Designing novel bisquinoline antimalarials from historical 4-aminoquinolines to combat drug-resistant malaria.
Mason J Handford, Yuexin Li, Terry Riscoe, Xiaowei Zhang, Jane X Kelly, Michael K Riscoe
Abstract read
In one paragraphArticle in Antimicrobial agents and chemotherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
6 authors.
Mason J HandfordChemical Physiology and Biochemistry Department, Oregon Health & Science University, Portland, Oregon, USA.ORCID 0000-0001-6764-3893 Yuexin Li *Experimental Chemotherapy Lab, Portland VA Research Foundation, Portland, Oregon, USA.
Terry Riscoe *Experimental Chemotherapy Lab, Portland VA Research Foundation, Portland, Oregon, USA.
Xiaowei Zhang *Experimental Chemotherapy Lab, Portland VA Research Foundation, Portland, Oregon, USA.
Jane X KellyExperimental Chemotherapy Lab, Portland VA Research Foundation, Portland, Oregon, USA.
Michael K RiscoeExperimental Chemotherapy Lab, Portland VA Research Foundation, Portland, Oregon, USA.ORCID 0000-0002-1343-5279 Funding
Second-Generation Novel Liver Stage Active AntimalarialsR01AI158533 · NIAID · PORTLAND STATE UNIVERSITY · PI KELLY, JANE X, ROTH, ALISON ELIZABETH · 2021 to 2025
$3.3MThe development of novel 4-aminoquinolines as therapeutics against multi-drug resistant Plasmodium falciparumF31AI174772 · NIAID · OREGON HEALTH & SCIENCE UNIVERSITY · PI HANDFORD, MASON JAMES · 2024 to 2025
$105kNIH HHS F31 AI 174772NIH HHS R01 AI 100569, R01 AI 141412, R01 AI 182513, R56 AI 182513NIH HHS R01 AI 158533U.S. Department of Defense HT94252410473, PR181134U.S. Department of Defense W81XWH2210494U.S. Department of Veterans Affairs 1I01 BX005674U.S. Department of Veterans Affairs I01 BX 003312, 2I01BX003312-10
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Indexed as
AminoquinolinesAntimalarialsMalaria, FalciparumPlasmodium falciparumQuinolinesAnimalsDrug ResistanceHumansMiceStructure-Activity Relationship4-aminoquinolineAminoquinolinesAntimalarialsQuinolines4-aminoquinolineantimalarial agentsmalariamultidrug-resistant malariaPlasmodium falciparum
Identifiers
PMID41770301
PMCPMC13041310
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390